ArticleMaterials (Basel, Switzerland)2022
Compositional Tailoring of Mg-2Zn-1Ca Alloy Using Manganese to Enhance Compression Response and In-Vitro Degradation.
Article in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 11 citations in OpenAlex.
- Advances in osseointegration of biomimetic mineralized collagen and inorganic metal elements of natural bone for bone repair.Regenerative biomaterials · 2023Review
- In vitro cytotoxicity and osteogenic potential of quaternary Mg-2Zn-1Ca/X-Mn alloys for craniofacial reconstruction.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
The present study investigates Mg-2Zn-1Ca/XMn alloys as biodegradable implants for orthopedic fracture fixation applications. The effect of the presence and progressive addition of manganese (X = 0.3, 0.5, and 0.7 wt.%) on the degradation, and post-corrosion compressive response were investigated. Results suggest that the addition of manganese at 0.5 wt.% improved the corrosion resistance of Mg-2Zn-1Ca alloys. The pH values stabilized for the 0.5Mn-containing alloy and displayed a lower corrosion rate when compared to other Mg-2Zn-1Ca/Mn alloys. Mg-2Zn-1Ca showed a progressive reduction in the compressive strength properties at the end of day 21 whereas Mg-2Zn-1Ca/0.3Mn and Mg-2Zn-1Ca/0.5Mn samples showed a decrease until day 14 and stabilized around the same strength range after day 21. The ability of Mg-2Zn-1Ca/0.5Mn alloy to develop a network of protective hydroxide and phosphate layers has resulted in the corrosion control of the alloy. Mg-2Zn-1Ca/0.7Mn displays segregation of Mn particles at the grain boundaries resulting in decreased corrosion protection. The mechanism behind the corrosion protection of Mg-2Zn-1Ca alloys was discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.